Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

← catalyst calendar

NCT03838926 · readout ≤ 499 d

Sponsored by Vanda Pharmaceuticals (industry) · VNDA — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Na · None · Treatment

Enrollment

42estimated

Sites

Countries

Poland, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2018-09-27

actual

When the study began enrolling

Primary completion

Dec 2027

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Dec 2027

estimated

The whole study's end, after follow-up

First posted

2019-02-12

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-03-16

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Relapsed or Refractory Hematologic Malignancies

Intervention

Drug: Trichostatin A

Primary outcomes

what the primary-completion date above is the date OF

Safety and tolerability of trichostatin A measured by spontaneous reporting of adverse events (AEs)

measured Up to 24 months

Dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of trichostatin A

measured Up to 24 months

Publications

PMID 40758573 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · VNDA's whole pipeline · Catalyst calendar · Every registered study · What changed